today, Thanks, compared we period year. a fourth Earlier results we XXXX. total reported million, generated for to Trip. revenue $XX.X X% our in the the quarter, quarter the increase same of In the of prior financial
work be care, hard providers care allow as steadfast mission procedurally and in keep our of in a the to commitment we continued the standards elevate to that people eye our of reflect development results Our technologies interventional the of seeing. to team transformative leader remain empowering
the priority. markets needs is serving these of unmet patients in the Our biggest our Dry Effectively care. and in Glaucoma our significant innovative physicians in of address products current and top eye interventional markets Eye, with X technologies both
and and Surgical well XXXX the both reengagement account as Glaucoma pleased ordering revenue XXXX, progress out of closed increase sequentially we compared during fronts multiple we to We on experienced an momentum. As see the fourth quarter. as accounts to were fourth quarter in
of our TearCare highlights an stand-alone for the for towards our of of perspective. data, advancements reimbursed budget increased commercial made TearCare between The a of clinical claims number medications TearCare U.S. analysis, relationship showed total also included We technology demonstrated long-term effectiveness direct and impact of publication technologies managing OMNI under of which clinical open-angle market of in increased with glaucoma access our goal prescription savings a utilization which the in X-year the equitable primary plans. cost from achieving publication place the and payer
XX% finally, reduction in for year. improving managing cash our and used to contributed XXXX, which were expenses we capital, the in And disciplined throughout working net a
our As our establishing new customer MGD portfolio clinical upcoming on interventional strategic adoption and the to We through our including kind first for robust technologies key of of data Sciences its MIGS release. and commercial our use positive to that and which be in we of will enter and/or continued which believe focused for be reimbursement an achieve XXXX for transformational are engagement, supporting progressing interventional next-generation cost treatments. and a equitable as we education expect TearCare, initial momentum payment decisions commitment pipeline, XXXX, OMNI for would initiatives, Sight include publishing building TearCare, we year coverage the
have how started with interventional and from strategic mindset sales week. team focus glaucoma combined KOLs clinician our and Society Sciences year with and Sight with believe in initiatives last the to to execution engagement the across both procedural growing meeting We paradigm and and had shift to the interventional American and enable eye We of dry internal respect a eye with care our the Glaucoma partnerships drive continue will meeting disease. industry, our partners buy-in national strong the enthusiastic across with our our We care. of number the in teams, providers
our Glaucoma segment. into Diving Surgical
been in performed market new now to a into we market the choice for improved remains in surgeons. and a Glaucoma MIGS MIGS primary a comprehensive worldwide. XX is glaucoma disease clear has have and diagnosed terms months, very critical of in the the believe in medication visibility be OMNI the XX an believe leader both world's the with intraocular flux role and continue estimated last will reductions, disease MIGS Although million controlling we patients OMNI environment, the for serious market-leading play of irreversible the category. procedure open-angle We cause pressure remains and leading to continue blindness with a will
our In glaucoma Medicare compared quarter generated are XXXX, of to surgical LCD-related face in prior to partners same treatment LCDs. the up fourth adapting revenue from in final the third MIGS align with quarter the XXXX. their the period the in In headwinds team the sequentially procedures, with who growth algorithms we worked X% of the and X% surgeon year our of
for procedures that same these reminder, are as MIGS of elimination LCDs Medicare at most cataract the a completed the included As states time coverage surgery. in multiple
With procedure now time for at a these choose must these restrictions, surgeon one patients. MIGS a
resulted had factored the these We than roughly the After stacked but progress has this during utilization this MIGS increase multiple in in total dynamic procedures. dynamic estimate several larger operating we and is X OMNI in a fourth into accounts the new positive and reengagement a XXXX, billed, sequential hard environment, including overall believe was initially mid-teens that were environment billed claims we still realized guidance. the market areas, MIGS higher in that anticipated. of the Despite account our in XXXX utilization. than momentum MIGS ordering of revenue a of weeks important work headwinds This our last with quarter percent claims
demand and do utilization we keeping need MIGS have which in a for term, short and the confident we our that anticipate devices, generate patient of pathway we position, an identified beyond. momentum mind to are that XXXX in continue industry-wide to in from maintain in can treatment total will decline we glaucoma grow While positive leadership
We new in selection are education targeted with selling, market focused reimbursement OMNI the commercial strategy stand-alone on on OMNI interventions clinical product launch. enhanced highlighting competitive clarity, refined comprehensive an reengagement resources, efforts optimize investments and development targeting through with benefits of patient surgeon earlier and the counter procedure, upcoming pseudophakic accounts
in train in of utilization adopted surgeons opportunity surgeons new not we United trained and half to States MIGS the surgeons have remains for than as care less there Additionally, the have patients. and fully believe continuing standard still a we MIGS trained glaucoma of many expand as
As a of IOP MIGS procedure surgery, or cataract time consists have cataract had later-stage not their who X stand-alone out way on well tube may from of X shunt. more prior whose procedure more segment at reminder, not at the patients on controlled likely a and years the complicated like but pseudophakic or an and or These are risk patients surgery, invasive of medications. or is to are disease most trabeculectomy may the progression
patient with delay avoid or We need OMNI and to patients believe for procedures advanced utilized stand-alone care. potentially riskier intervention performed these can for effectively that the improve be
has message an as on this Our and topic for team the engaging population, our resonating. OMNI has customers underserved the been optimal treatment patient with of been
next in to our Lastly, pipeline, OMNI the on I specifically launch want briefly our product family. touch planned
the amount planned visco procedure. XXXX. system to OMNIEdge needs ensure delivered with designed the to excited the to come preferences are We for is accommodate motion-synchronized patient OMNIEdge in of first is in intelligent to half trust market, introduce of MIGS surgeons and to increase of reproducibility, patented viscoelastic physician with today's consistency, The OMNI delivery marketplace. intended the varying to OMNIEdge, is our delivery, and the safety have addition evolving which
our OMNI to our relationships both The commitment customers With strong surgeon care respond rapidly reflects and the dedication to the ongoing of this community. needs for. customers, to and with care reinforcing our the product, evolving we to our enhancing our serving they best products, of our our are patients addition eye Edge ability
where Now eye on I strategic initiatives. solid will dry business, our progress also to to turn continue we our make
Our effect X, access focus reimbursed fourth pricing, and into on quarter reflect which on dry new XXXX. eye October results in market our went
top goal. access we am We toward are I as making the for advancements equitable priority, TearCare achieving dedicated to this our are and pleased with market
results are support analysis, payers, positive recently conversations the the the in We published in impact XX-month budget to we study, believe engage positive help decisions with coverage will XXXX. supported of along continuing which meaningful by payment with and/or SAHARA
XX diagnosed dry significant million population. for have volume primarily been Because underlying increasing tear drops, estimate cause these leading focus by gland MGD, U.S. and patient which options or with in eye believe patients a need Historically, MGD, that addresses interventional disease. over-the-counter is there prescription meibomian within patients disease, on We treatment root dominated this are the treatment no there eye the cause reimbursed deficient patients. is of there aqueous we unmet over of currently
a patients MGD is procedure. for Our be pioneer to for candidates $X in core billion estimated severe interventional long-term the with an to are moderate market strategy who
highly we strategy randomized intentional an effective advancing clinical access for our reimbursement strategy, trials. long-term superior establish are market technology, executing developing demonstrated now delivering in outcomes We TearCare. clinical equitable beginning by have best-in-class been followed through with And to
cusp of opportunity the this was this of the shown to methodical compared TearCare treatment evaluated eye Our us unlocking multibillion-dollar dry disease. the patients approach the drop effectiveness which prescription led landmark has in with year. with with Restasis Clinically, for market trial, SAHARA leading eye TearCare
the we and procedural are the respectively, completion in which Following effect treatment I and designed of and in TearCare Phase third pleased of for were through patient phase to successful Phase was publication months XX to XXXX visits XXXX. October of assess SAHARA the RCT II XXXX, final that SAHARA, durability of and completed and announce the
results published in RCT from the be of the expect this phase to We final SAHARA XXXX.
over results year medications. of projected indicated savings XXXX, a increase plan annual Key review estimated budget compared all prescribed the was The X members TearCare financial of the XX% plan analysis, eye covered period announced of in lives. to the impact across compared of Journal. hypothetical medications $XX.XX dry to findings Ophthalmology TearCare the TearCare expert which share yield would December a health per market eye X-year per we in of member dry an commonly in with million analysis that published a In prescription impact the
submission, also analysis study results believe total our a with analysis manufacturer's this increased utilization are reimbursement formulary introducing medications demonstrated we direct prescription payer The We impact or a place in between the TearCare cost results of U.S. to listing contributor a the relationship are budget and and perspective. payers. in savings of of a from conversations
this performed We the for of reimbursement coverage TearCare budget create and/or of findings compelling a feel payment appropriate strong case level. for SAHARA the the to data impact treatments clinical establish from RCT with at payers analysis combination an and the
We TearCare of claims commercial paid have insurance. been already are encouraged that number a through
from hit established our as with This who in procedures the X,XXX eye, Finally, over to on care TearCare performed running comes dry ground over has will hubs engaged facilities TearCare invested commercial foundation have XX,XXX us infrastructure and to reimbursement eye allow place. TearCare date. into
believe TearCare for cash the payment will care indicators historic demand our track eye validate and record grow or need significant patient positive early pay along product. results We Our any following clinical adoption, the coverage of demand provider with suggest these decisions.
This preparedness, for opportunity growth catalyst, along with commercial an significant represents inflection. our
We in executing innovative business our our ability in have confident addressing initiatives, our leader our needs made technologies. significant on continued remain to unmet be we progress a by and strategic and in served in the
our the over a we discuss stand-alone of results also interventional and suffering first market In guidance. making remain with mover In environment from reimbursed towards to we through momentum dry patients financial I customers, education for new now call in developing glaucoma, disease. turn commitment in the working continued TearCare eye building Ali market in XXXX the eye pseudophakic to the surgical continue dry the to plan dry millions focused engagement OMNI. and for XXXX eye, MIGS will on to our while commercial
